Asset

ADALTA LIMITED

1AD
equity
AUD $0.040
stockPerformance 0.00 (0%)
Updated: 20 Jan, 5:10 am UTC
02 Jan04 Jan08 Jan11 Jan13 Jan17 Jan20 Jan0.03850.0390.03950.040.04050.0410.04150.0420.04250.0430.04350.0440.0445
Description
Adalta Limited is an ASX-listed biotechnology company focused on the development of innovative therapies for the treatment of chronic diseases. Adalta’s core objective is to develop innovative antibody-based therapies for the prevention and treatment of chronic diseases such as inflammation, fibrosis and cancer. The company’s current operations include, a Phase 2 clinical study of its lead product, AD-114, a novel anti-PD-L1 antibody for the treatment of solid tumours, and pre-clinical programs for other novel antibodies targeting inflammatory diseases, fibrosis and cancer.